Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions
出版年份 2016 全文链接
标题
Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions
作者
关键词
-
出版物
PROTEIN ENGINEERING DESIGN & SELECTION
Volume 29, Issue 10, Pages 457-466
出版商
Oxford University Press (OUP)
发表日期
2016-08-31
DOI
10.1093/protein/gzw040
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
- (2016) M. Bacac et al. CLINICAL CANCER RESEARCH
- RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis
- (2016) P. Bru nker et al. MOLECULAR CANCER THERAPEUTICS
- ITOC2 – 037. CEA TCB, A novel T-cell bispecific antibody with potent in vitro and in vivo antitumour activity against solid tumours
- (2015) Marina Bacac et al. EUROPEAN JOURNAL OF CANCER
- Highly reduced binding to high and low affinity mouse Fc gamma receptors by L234A/L235A and N297A Fc mutations engineered into mouse IgG2a
- (2015) E. Arduin et al. MOLECULAR IMMUNOLOGY
- Structure of FcγRI in complex with Fc reveals the importance of glycan recognition for high-affinity IgG binding
- (2015) Jinghua Lu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Structural basis for binding of human IgG1 to its high-affinity human receptor FcγRI
- (2015) Masato Kiyoshi et al. Nature Communications
- Abstract 4573: A novel bispecific Fap-Dr5 antibody inducing potent and tumor-specific death receptor 5 (Dr5) activation by fibroblast activation protein (Fap)-dependent crosslinking
- (2015) Katharina Wartha et al. CANCER RESEARCH
- Abstract PR8: Novel tumor-targeted, engineered IL-2 variant (IL-2v)-based immunocytokines for immunotherapy of cancer.
- (2014) Christian Klein et al. CANCER RESEARCH
- Hepatocyte clearance and pharmacokinetics of recombinant factor IX glycosylation variants
- (2013) Eric Blasko et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Effects of altered FcγR binding on antibody pharmacokinetics in cynomolgus monkeys
- (2013) Maya K Leabman et al. mAbs
- Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies
- (2013) Tilman Schlothauer et al. mAbs
- An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations
- (2013) Omid Vafa et al. METHODS
- Isotype and glycoform selection for antibody therapeutics
- (2012) Roy Jefferis ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
- GA201 (RG7160): A Novel, Humanized, Glycoengineered Anti-EGFR Antibody with Enhanced ADCC and Superior In Vivo Efficacy Compared with Cetuximab
- (2012) C. A. Gerdes et al. CLINICAL CANCER RESEARCH
- Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond
- (2012) P. Mark Hogarth et al. NATURE REVIEWS DRUG DISCOVERY
- Modulation of antibody effector function
- (2011) John R. Desjarlais et al. EXPERIMENTAL CELL RESEARCH
- Advances in the assessment and control of the effector functions of therapeutic antibodies
- (2011) Xu-Rong Jiang et al. NATURE REVIEWS DRUG DISCOVERY
- A Medicinal Chemist’s Guide to Molecular Interactions
- (2010) Caterina Bissantz et al. JOURNAL OF MEDICINAL CHEMISTRY
- IgG2m4, an engineered antibody isotype with reduced Fc function
- (2010) Zhiqiang An et al. mAbs
- Activating and inhibitory Fcγ receptors in immunotherapy: being the actor or being the target
- (2009) Riad Abès et al. Expert Review of Clinical Immunology
- Structural characterization of a human Fc fragment engineered for lack of effector functions
- (2008) Vaheh Oganesyan et al. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- Specificity and affinity of human Fc receptors and their polymorphic variants for human IgG subclasses
- (2008) P. Bruhns et al. BLOOD
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started